Does lymph node ratio impact survival in resected periampullary malignancies?

American Journal of Surgery

Volumn 197, Issue 3, 2009, Pages 348-352

  Hurtuk, Michael G ^a   Hughes, Christopher ^b   Shoup, Margo ^a   Aranha, Gerard V ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Ampullary adenocarcinoma; Cholangiocarcinoma; Duodenal adenocarcinoma; Lymph node ratio; Pancreatic adenocarcinoma; Pancreaticoduodenectomy

Indexed keywords

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER STAGING; DUODENUM CARCINOMA; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; VATER PAPILLA; VATER PAPILLA CARCINOMA;

ABDOMEN; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AMPULLA OF VATER; CHOLANGIOCARCINOMA; COMMON BILE DUCT NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; DUODENAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 60549083986     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2008.11.010     Document Type: Article

References (33)

1. Yeo C.J., Cameron J.L., Sohn T.A., et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 226 (1997) 248-257
2. Benassai G., Mastrorilli M., Mosella F., et al. Significance of lymph node metastases in the surgical management of pancreatic head carcinoma. J Exp Clin Cancer Res 18 (1999) 23-28
3. Lim J., Chien M.W., and Earle C.C. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 237 (2003) 74-85
4. Breslin T.M., Hess K.R., Harbison D.B., et al. Neoadjuvent chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8 (2001) 123-132
5. Sohn T.A., Yeo C.J., Cameron J.L., et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4 (2000) 567-579
6. Kuhlmann K.F., de Castro S.M., Wesseling J.G., et al. Surgical treatment of pancreatic adenocarcinoma: actual survival and prognostic factors in 343 patients. Eur J Cancer 40 (2004) 549-558
7. Han S.S., Jang J.Y., Kim S.W., et al. Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 32 (2006) 271-275
8. Siewert J.R., Bottcher K., Stein H.J., et al. Relevant prognostic factors in gastric cancer: ten-year results of the German gastric cancer study. Ann Surg 228 (1998) 449-461
9. Kologlu M., Kama N.A., Reis E., et al. A prognostic score for gastric cancer. Am J Surg 179 (2000) 521-526
10. Tachibana M., Dhar D.K., Kinugasa S., et al. Esophageal cancer with distant lymph node metastasis: prognostic significance of metastatic lymph node ratio. J Clin Gastroenterol 31 (2000) 318-322
11. Lee JH, Noh SH, Lah KH, et al. The prognosis of stage IV gastric carcinoma patients after curative resection. Hepatol Gastroenterol 201;48:1802-5.
12. Inoue K., Nakane Y., Iiyama H., et al. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol 9 (2002) 27-34
13. Hyung W.J., Noh S.H., Yoo C.H., et al. Prognostic significance of metastatic lymph node ratio in T3 gastric cancer. World J Surg 26 (2002) 323-329
14. van der Wal B.C., van der Butzelaar R.M., Meij S., et al. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol 28 (2002) 481-489
15. Berger A.C., Watson J.C., Ross E.A., et al. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 70 (2004) 235-240
16. Voordeckers M., Van de Vinh-Hung V., Steene J., et al. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol 70 (2004) 225-230
17. Santiago R., Munoz J.M., Marti E., et al. Metastatic lymph node ratio as a prognostic factor in gastric cancer. Eur J Surg Oncol 31 (2005) 59-66
18. Sierzega M., Popiela T., Kulig J., et al. The ratio of metastatic/resected lymph nodes is an independent prognostic factor in patients with node-positive pancreatic head cancer. Pancreas 33 (2006) 240-245
19. De Ridder M., Van Vinh-Hung V., Nieuwenhove Y., et al. Prognostic value of the lymph node ratio in node positive colon cancer. Gut 55 (2006) 1681
20. Yildirim E., and Berberoglu U. Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients. World J Surg 31 (2007) 276-289
21. Pawlik T.M., Gleisner A.L., Cameron J.L., et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 141 (2007) 610-618
22. Lee H.Y., Choi H.J., Park K.J., et al. Prognostic significance of metastatic lymph node ratio in node-positive colon carcinoma. Ann Surg Oncol 14 (2007) 1712-1717
23. Chan J.K., Kapp D.S., Cheung M.K., et al. The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients. Br J Cancer 97 (2007) 605-611
24. Slidell M.B., Chang D.C., Cameron J.L., et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 15 (2008) 165-174
25. Pedrazzoli S., DiCarlo V., Dionigi R., et al. Standard versus extended lymphadenectomy associated with pancreaticoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective randomized study. Lymphadenectomy Study Group. Ann Surg 228 (1998) 508-517
26. Yeo C.J., Cameron J.L., Lillemoe K.D., et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. Part 2: Randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 236 (2002) 355-366
27. Schwarz R.E., and Smith D.D. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol 13 (2006) 1189-1200
28. Schwarz R.E., and Smith D.D. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol 13 (2006) 1189-1200
29. Henne-Bruns D., Vogel I., Luttges J., et al. Surgery for ductal adenocarcinoma of the pancreatic head: staging, complications, and survival after regional versus extended lymphadenectomy. World J Surg 24 (2000) 595 601
30. Tomlinosn J.S., Jain S., Bentrem D.J., et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg 142 (2007) 767-774
31. Pawlik TM, Abdalla E, Barnett C, et al. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg 140:584-91.
32. American Joint Committee on Cancer. Staging (2002), Springer-Verlag NY, Chicago, IL
33. Bilimoria K.Y., Talamonti M.S., Wayne J.D., et al. Effect of hospital type and volume on lymph node evaluation for gastric and pancreatic cancer. Arch Surg 143 (2008) 671-677